Researchers from Monash University have developed a new drug delivery strategy able to block pain within the nerve cells, in what could be a major development of an immediate and long lasting treatment for pain.
More than 100 million Americans suffer from chronic pain and this figure is expected to grow, driven by the increased life expectancy, increasing incidence of diabetes and cancer, combined with better survival rates, often leaving patients with severe and poorly treated pain. The global market for nerve pain treatments is over US$600 billion and yet current pain therapies are not completely effective and often suffer from unwanted side effects.
Research published in the journal, Science Translational Medicine, reveals how a target protein, long known to be associated with both chronic and acute pain, works within the nerve cell. This protein is the NK1 receptor, the receptor of the neuropeptide substance P, which mediates pain transmission. Because of its association with pain and other diseases of the nervous system, many drug development attempts have focused on inhibiting this receptor, but the efficacy of these treatments has been very limited. This new work shows that such ineffectiveness could be in part because the treatments targeted the protein on the surface of the nerve cell.
Dr Michelle Halls and Dr Meritxell Canals from the Monash Institute of Pharmaceutical Sciences (MIPS) and the ARC Centre for Excellence in Bio-Nano Science (CBNS) at Monash University, have worked with Professor Nigel Bunnett, previously at Monash and now at Columbia University in the US, and Professor Chris Porter from MIPS and CBNS.
Together they have found that the NK-1 receptor controls pain once it is inside the cell — so drugs that merely block it when it is on the surface of the cell have little efficacy. Instead, this new research shows that, in animal models, if the NK-1 receptor is blocked once it enters the nerve cell, it is possible to suppress pain more effectively.
Dr Halls said that the new strategy of “targeting receptors inside the cell represents a new frontier in drug delivery and a novel therapeutic strategy for dealing with pain.”
Working with a multidisciplinary team of cell biologists, pharmacologists, physiologists and drug delivery experts, the researchers developed drugs that specifically target NK-1 receptors within the nerve cell. Animal studies showed that using the drugs — which have an engineered lipid attachment that targets the drug to the NK-1 receptor inside the cell, could block pain for extended periods in several animal models.
Dr Canals said: “This is a proof-of-concept study that shows that we can re-engineer current pain drugs and make them more effective. The challenge is now to translate the technology into human clinical trials. This is a complex and challenging path — but the ultimate benefits to patients with nerve pain are potentially highly significant.”
The Latest on: Pain relief
Natural Pain Relief is as Close as Your Garden
on July 11, 2018 at 1:40 pm
Busy schedules, over indulging, and strenuous summer activities can lead to sore muscles, indigestion and headaches. When searching for pain relief, look no further than your own garden or your local ... […]
Grow A Garden of Pain Relief
on July 11, 2018 at 8:46 am
Suffering from a stiff neck? What about an achy back? Approximately one-third of Americans report they feel aches and pains “very often” or “often”— more than people in any other country, according to ... […]
FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
on July 11, 2018 at 5:13 am
Joint Surgery The agency is now mandating that HCPs involved in managing patients with pain, including prescribers but also nurse practitioners and pharmacists, be trained on all available treatment o... […]
How To Get Relief From Pain — Fast
on July 10, 2018 at 10:03 pm
Today, pain relievers can quickly rid us of our aches, but it wasn’t always that way. For centuries, humans looked for ways to alleviate pain using things like herbs and heating pads to bring some com... […]
Waldorf woman learns how to overcome chronic pain with opioid-free treatment
on July 10, 2018 at 9:17 pm
On April 26, 1999, Tijuana Adams of Waldorf welcomed a baby girl named Kaitlyn Adams into the world, not knowing that her daughter would need a life-saving bone marrow transplant several years later a... […]
via Google News and Bing News